Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):June 29, 2004
MOLECULAR DEVICES CORPORATION
Delaware
| 0-27316 (Commission File Number) | 94-2914362 (IRS Employer Identification No.) |
1311 Orleans Drive
Sunnyvale, CA 94089
Registrant’s telephone number, including area code:(408) 747-1700
| Item 5. Other Events and Regulation FD Disclosure | ||||||||
| Item 7. Financial Statements and Exhibits | ||||||||
| SIGNATURES | ||||||||
| INDEX TO EXHIBITS | ||||||||
| EXHIBIT 99.1 | ||||||||
Table of Contents
Item 5. Other Events and Regulation FD Disclosure
On June 29, 2004, Molecular Devices Corporation (“Molecular Devices”) sent a letter to Institutional Shareholder Services in which Molecular Devices agreed that, without the prior approval of the company’s stockholders, options issued under any of Molecular Devices’ existing stock option plans will not be repriced, replaced or regranted through cancellation, or by lowering the option exercise price of a previously granted award. Molecular Devices’ existing stock option plans, including its 1995 Stock Option Plan, as amended, will be amended at the next meeting of the Board of Directors of Molecular Devices to reflect these changes, and copies of the amended plans will be sent to Institutional Shareholder Services.
A copy of the letter regarding the amendment of Molecular Devices’ stock option plans is attached hereto as Exhibit 99.1.
Item 7. Financial Statements and Exhibits
(c) Exhibits.
| 99.1 | Letter dated June 29, 2004, from Molecular Devices to Institutional Shareholder Services. |
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| MOLECULAR DEVICES CORPORATION | ||||
| Dated: June 29, 2004 | By: | /s/ TIMOTHY A. HARKNESS | ||
| Timothy A. Harkness | ||||
| Vice President and Chief Financial Officer | ||||